Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29078046 | 0.82 | CNR2 (0.36) | BACE1MAPTHPGD | |
| SCHEMBL30473724 | 0.82 | CNR2 (0.36) | BACE1MAPTHPGD | |
| SCHEMBL21395337 | 0.81 | BACE1 (0.33) | BACE1 | |
| SCHEMBL1577309 | 0.78 | AAK1 (0.32) | — | |
| SCHEMBL17420947 | 0.76 | LMNA (0.41) | MAPTHPGDGAA | |
| SCHEMBL21713923 | 0.76 | GAA (0.36) | BACE1MAPTHPGDGAA | |
| SCHEMBL4513196 | 0.76 | GAA (0.37) | BACE1MAPTHPGDGAA | |
| SCHEMBL21713689 | 0.75 | MAPT (0.33) | BACE1MAPTHPGD | |
| SCHEMBL29069772 | 0.75 | — | — | |
| SCHEMBL14141944 | 0.75 | MBOAT4 (0.33) | MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4364804-A2 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | Janssen Pharmaceutica NV (BE) | 2024-05-08 | — | — | EP | disclosed |
| EP-3782996-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2024-04-10 | — | — | EP | disclosed |
| US-11897900-B2 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-13 | — | — | US | disclosed |
| EP-3833662-B1 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-17 | — | — | EP | disclosed |
| EP-3833662-B1 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2024-01-17 | — | — | EP | disclosed |
| US-20230047296-A1 | Nrf2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2023-02-16 | — | — | US | disclosed |
| US-20220315604-A1 | INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2022-10-06 | — | — | US | disclosed |
| US-11427601-B1 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | JANSSEN PHARMACEUTICA NV (BE) | 2022-08-30 | — | — | US | disclosed |
| EP-3833662-A2 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | Janssen Pharmaceutica N.V. (BE) | 2021-06-16 | — | — | EP | disclosed |
| CN-112930347-A | Inhibitors of KEAP1-Nrf2 protein-protein interactions | 詹森药业有限公司 | 2021-06-08 | — | — | CN | disclosed |
| EP-3307739-B1 | NRF2 REGULATORS | GLAXOSMITHKLINE IP DEV LTD (GB) | 2020-10-07 | — | — | EP | disclosed |
| US-10604509-B2 | Nrf2 regulators | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2020-03-31 | — | — | US | disclosed |
| US-20200079759-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2020-03-12 | — | — | US | disclosed |
| WO-2020041169-A2 | INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-27 | — | — | WO | disclosed |
| US-20200055874-A1 | INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION | JANSSEN PHARMACEUTICA NV (BE) | 2020-02-20 | — | — | US | disclosed |
| US-20180179187-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
| US-20180179187-A1 | Nrf2 REGULATORS | ASTEX THERAPEUTICS LIMITED (GB) | 2018-06-28 | — | — | US | disclosed |
| EP-3307739-A1 | NRF2 REGULATORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2018-04-18 | — | — | EP | disclosed |
| WO-2016202253-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-22 | — | — | WO | disclosed |
| WO-2016202253-A1 | NRF2 REGULATORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2016-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315604-A1 | INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION | KEAP1, NFE2L2, HMOX1 | BACE1 2167/4885MAPT 763/4885HPGD 152/4885 |
| US-20180179187-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | BACE1 1787/4885MAPT 2449/4885HPGD 275/4885 |
| US-11897900-B2 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | KEAP1, NFE2L2, HMOX1 | BACE1 2167/4885MAPT 763/4885HPGD 152/4885 |
| US-11427601-B1 | Inhibitors of KEAP1-Nrf2 protein-protein interaction | KEAP1, NFE2L2, HMOX1 | BACE1 2167/4885MAPT 763/4885HPGD 152/4885 |
| US-10604509-B2 | Nrf2 regulators | NFE2L2, KEAP1, NQO1 | BACE1 1787/4885MAPT 2449/4885HPGD 275/4885 |
| US-20200055874-A1 | INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION | KEAP1, NFE2L2, HMOX1 | BACE1 2167/4885MAPT 763/4885HPGD 152/4885 |
| US-20230047296-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | BACE1 1435/4885MAPT 2064/4885HPGD 223/4885 |
| US-20200079759-A1 | Nrf2 REGULATORS | NFE2L2, KEAP1, NQO1 | BACE1 1435/4885MAPT 2064/4885HPGD 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.